This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech Stock Mailbag: Clinical Data, Mannkind and Thanks!

BOSTON ( TheStreet) -- This is the last Biotech Stock Mailbag column in 2010. Call me a slacker but I'm exercising my right to give the Mailbag a much-needed holiday rest.

Before I get to your biotech stock questions and comments, let me take this opportunity to thank all of you for making the Mailbag -- now entering its fifth (!) year -- such an meaningful anchor in TheStreet's coverage of the biotech sector.

My personal feelings about the Mailbag and pretty much everything I try to do at TheStreet were summed up best in a recent email I received from David K.:

"I wanted to thank you again for replying to my comments in this week's Biotech Stock Mailbag article. Even if I don't always agree with your opinions or presentation of information, I am interested in what you have to contribute and I keep abreast of your work daily. One of the first items I read every morning is your column.

"I believe that you taking the time to interact with readers in the comments section of your articles or in a live discussion during panel hearings says a great deal about your work ethic. You are surely committed to providing readers, both friends and foes alike, an opportunity to actually be a part of your column. You create a sense of community (even if a hostile one) through making your column dynamic as opposed to other authors whose static blogs simply post an article and nothing more. Your efforts are commendable and I encourage you to keep up the good work."

Makes me blush. Thank you, David, for the very kind words, even though I like to think that I'm not the one instigating the hostilities. When pushed, however, I will push back.

I truly appreciate all the readers of this Mailbag, my columns and stories. That includes those of you who desperately need spell check (once again, it's l-o-s-e-r, not l-o-o-s-e-r) and even the die-hard conspiracy theorists who will never stop believing that I'm banking coin from hedge fund short sellers in an offshore account.

I get up every day and go to sleep every night trying to provide the best biotech coverage and commentary possible. Integral to that effort is being as interactive with you as I can, whether it's through columns like the Mailbag, live blogs, the commenting section of this web site, email or on Twitter. I want to help you make sense of this crazy, volatile biotech scene in which we're all so interested. The constant feedback, questions and comments you provide -- whether it's filled with praise or stinging with criticism -- are an invaluable and essential part of the equation.

Thanks again for spending another year with me. Happy Holidays and Happy New Year! Now, onto your emails:

My column elucidating the bear thesis on Clinical Data (CLDA) and its anti-depressant vilazodone prompted a response from the bulls.

Wedbush analyst Greg Wade, contrary to my hedge fund source, strongly believes FDA approves vilazodone on Jan. 22 and that the drug's peak sales will top $2 billion.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ABT $46.75 0.54%
DEPO $22.67 3.70%
DCTH $1.01 -3.80%
MNKD $5.24 2.40%
PFE $34.51 1.00%

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs